NASDAQ · PIII
Healthcare · Medical - Care Facilities
$7.61
Up+$0.27 (+3.55%)
Updated Sep 17, 2026, 8:15 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PIII closed at $7.61 after 20 trading sessions, down 25.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $7.86 | $8.18 | $7.58 | $7.61 | 20.81K |
| Sep 15, 2026 | $8.31 | $8.48 | $7.96 | $7.97 | 15.63K |
| Sep 14, 2026 | $8.26 | $8.545 | $8.21 | $8.21 | 31.01K |
| Sep 11, 2026 | $8.425 | $8.60 | $8.25 | $8.43 | 40.27K |
| Sep 10, 2026 | $8.40 | $8.55 | $8.25 | $8.36 | 9.98K |
| Sep 9, 2026 | $9.00 | $9.00 | $8.42 | $8.42 | 8.84K |
| Sep 8, 2026 | $9.32 | $9.32 | $8.90 | $8.98 | 21.29K |
| Sep 4, 2026 | $9.20 | $9.35 | $9.11 | $9.35 | 13.26K |
| Sep 3, 2026 | $9.2226 | $9.49 | $8.97 | $9.13 | 19.51K |
| Sep 2, 2026 | $8.89 | $9.4855 | $8.89 | $9.41 | 17.81K |
| Sep 1, 2026 | $9.13 | $9.24 | $8.79 | $8.89 | 56.22K |
| Aug 31, 2026 | $9.14 | $9.14 | $8.84 | $9.06 | 6.74K |
| Aug 28, 2026 | $9.70 | $9.745 | $8.75 | $9.22 | 48.94K |
| Aug 27, 2026 | $9.79 | $10.00 | $9.39 | $9.39 | 38.52K |
| Aug 26, 2026 | $10.08 | $10.39 | $9.92 | $9.92 | 10.66K |
| Aug 25, 2026 | $10.03 | $10.31 | $9.39 | $10.31 | 42.86K |
| Aug 24, 2026 | $10.31 | $10.36 | $10.00 | $10.03 | 14.32K |
| Aug 21, 2026 | $10.235 | $10.3866 | $10.0801 | $10.31 | 7.03K |
| Aug 20, 2026 | $10.4165 | $10.5599 | $9.95 | $10.34 | 14.62K |
| Aug 19, 2026 | $10.76 | $10.76 | $10.15 | $10.27 | 10.01K |
The latest Smart Investors Daily articles mentioning PIII.
PIII research
Company profile and research snapshot.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 22, 2026 | TD Cowen | Hold | — |
| May 15, 2026 | Lake Street | Buy | — |
| Apr 2, 2026 | TD Cowen | Hold | — |
| Mar 27, 2026 | Lake Street | Buy | — |
| Nov 17, 2025 | Lake Street | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 10, 2026
P3 Health Partners (NASDAQ:PIII) narrows FY2026 sales outlook from $1.500 billion-$1.650 billion to $1.500 billion-$1.600 billion vs $1.524 billion estimate.
Benzinga · Jun 4, 2026
Yahoo · Jan 8, 2026
The recent move to a reduced US$12.50 price target for P3 Health Partners, alongside an unchanged fair value estimate of US$10.25, signals a recalibration of expectations rather than a rewrite of the core story. Bullish analysts see the updated target as a reset on timing after weaker Q3 aEBITDA, while still pointing to underlying operational progress that they believe is not fully showing up in the numbers yet. As you read on, keep an eye on how these differing views shape the evolving...
defenseworld.net · Dec 3, 2025
P3 Health Partners (NASDAQ: PIII - Get Free Report) and CVR Medical (OTCMKTS:CRRVF - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation. Volatility and Risk P3 Health Partners has
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PIII.
